Categories

Tag: GLP-1

Three Agencies Could Define GLP-1 Friendly. None Has.

By HANA KAHLEOVA

Almost every week, a patient asks me some version of the same question. If drugs like Ozempic work by copying a hormone my gut already makes, can the right food do what the injection does?

Food and supplement marketers have already answered yes. Frozen dinners now carry GLP-1 Friendly badges. Supplement ads promise the drug’s effects in a capsule. Hundreds of products invoke the hormone, aimed at the roughly 12 percent of U.S. adults who have taken one of these medications. Yet the term has no federal definition. The U.S. Department of Agriculture, which has approved the phrase on some labels, has stressed that its approvals do not create a standard. In March, Kyle Diamantas, then the Food and Drug Administration’s top food official and now its acting commissioner, told Bloomberg Law the agency was aware of the issue but had no action planned.

The result is a marketing claim that borrows the name of a hormone, falls between three regulators and has been tested by none of them. For a health system still deciding who should get these drugs and who should pay for them, that is not a side issue. It shapes what patients think they can buy instead.

What the Science Supports

As a clinical researcher who studies diet and type 2 diabetes, I think the honest answer is more interesting than the label. Food really can raise the body’s own GLP-1. The hormone is released by cells lining the intestine within minutes of a meal and, hours later, in response to compounds gut bacteria make from fiber.

But the evidence does not support single-ingredient claims. A scoping review published in July gathered 52 trials of isolated fibers. Most tested a single dose, the typical trial enrolled 19 people, and fewer than a third found any rise in GLP-1.

The strongest signal my colleagues and I have found came from a whole meal. In a randomized crossover trial, 60 men, 20 of them with type 2 diabetes, ate two breakfasts with the same calories and proportions of carbohydrate, protein and fat: a tofu burger with green tea, or a processed pork-and-cheese burger with a sweetened latte. After the plant-based meal, GLP-1 secretion was 30.5 percent higher in the men with diabetes, and measures of insulin secretion and beta-cell function improved. The meals also differed in fiber, saturated fat and sugar, so we cannot say which difference mattered. What moved the hormone was a pattern of eating, not a molecule.

Continue reading…

Midlife Women Are Being Handed GLP-1s. Who Is Asking About Their Bones?

By HANA KAHLEOVA

Tuesday October 20th was World Osteoporosis Day, and one number deserves more attention than it gets: one in two women over 50 will break a bone because of osteoporosis. Bone loss speeds up as estrogen falls during menopause. Yet in the rush to treat midlife weight gain with the newest drugs, bones rarely come up.

I think of a patient who sat down and named the drug before she said anything else. She was in her early 50s, and she wanted a GLP-1, the weekly injection everyone seems to be on now. She had gained weight around her middle that nothing would touch, and she had not slept through the night in months. Two or three times a night she woke up soaked, kicked off the covers and lay awake. Two of her friends had started the drug that spring. She expected a prescription, not a conversation.

She is a composite of women I have treated, but her request is common. About one in five adults ages 50 to 64 have taken a GLP-1 drug, the highest share of any age group. Many are women looking for relief from the weight gain and broken sleep of the menopause transition.

They have good reason to want something that works. For generations, women’s menopause symptoms were minimized or left for them to endure. A drug that finally does something can feel like overdue respect. In a 15-minute visit, it is also the fastest thing a doctor can offer. That is not an unreasonable choice. The question is whether it should be the first one.

What changed my answer for this patient was a line already in her chart. A bone density scan the year before had shown osteopenia, the thinning that comes before osteoporosis. It had earned a note to keep an eye on it and then dropped out of the conversation, as these findings so often do.

Here is why it mattered. The weight people lose on GLP-1 drugs is not all fat. Across clinical trials of these medications, roughly a quarter of the weight lost was lean mass. In one retrospective study of patients taking semaglutide or tirzepatide, bone density at the hip fell by nearly 3% over about three years. For a woman already losing bone as estrogen declines, rapid weight loss lands on top of an existing deficit. And about half of patients stop semaglutide within a year, often regaining weight, so some pay that cost without keeping the benefit.

Continue reading…

Beyond the Scale: How organizations should evaluate the success of obesity management solutions

By CAITLYN EDWARDS

Obesity treatment is often framed as a race to the bottom — how much weight can someone lose? Five percent? Ten percent? And with recent scientific advancements in anti-obesity medications such as GLP-1s, what about even 15-20%?

Obesity treatment, though, isn’t just about the number on the scale. It’s about moving the needle on biomarkers that really matter to overall health. Seven out of the top ten leading causes of death and disability in the United States today are chronic diseases that have links to overweight and obesity. The metabolic benefits of just 5% weight loss can be life-changing for many people with obesity-related comorbidities. This means that for organizations looking to treat their chronic conditions, obesity care shouldn’t be all about striving for the lowest possible weight.

Indeed, consensus and practice statements from groups including the American Heart Association, the American College of Cardiology, the American Diabetes Association, and The Obesity Society, support weight loss programs that achieve clinically significant weight loss outcomes, defined as greater than or equal to 5% of an individual’s baseline body weight. This number is derived from decades of research demonstrating that even modest weight loss has impacts on physiological health including type 2 diabetes, dyslipidemia, hypertension, and many kinds of cancer.

People who attain just 5% weight loss see the following health improvements:

  • Reductions in systolic and diastolic blood pressure
  • Risk reductions of developing type 2 diabetes by almost 60%
  • Reductions in HbA1c and fasting blood glucose levels
  • Greater insulin sensitivity
  • Decreased need for newly prescribed diabetes, hypertension, and lipid-lowering medications

Understanding that obesity outcomes include more than just the number on the scale, how can benefit managers and health plan leaders measure success? Here are some things organizations should look for when evaluating an obesity management solution:

N-size of outcomes

While a high weight loss average may sound impressive, it doesn’t tell the whole story. A better measure might be the number of people in a program able to achieve greater than 5% weight loss. The fact is that weight loss averages are easily skewed by outliers.  An exceptionally high average may not be representative of what is actually taking place at the individual level. What matters is that a large percentage of people in the program are able to see clinically significant results.

Emphasis on behavior change

Another way to measure the success of an obesity management solution is by the sustainability of its outcomes — primarily through adopting healthier behaviors. Intensive behavioral therapy is crucial to obesity treatment and can reduce the risk of type 2 diabetes. Support from expert dietitians and coaches can help promote a healthy relationship with food for optimal weight loss.

Through medical nutrition therapy, dietitians create personalized calorie and macronutrient goals to foster weight loss in a healthy, sustainable way. Also, self-directed cognitive behavioral therapy can help people become more aware of underlying thoughts and behavior patterns around food.

Step therapy approach to treatment

Some obesity management solutions avoid medications entirely while others rely solely on expensive GLP-1s. But both of those methods fall short of providing the best care to the most people at the lowest cost possible.

The best obesity management solutions take a clinically rigorous step-therapy approach to treatment. This way, they carefully manage access to expensive anti-obesity medications while achieving meaningful outcomes. Many of their members will achieve clinically significant weight loss through behavior change alone. Some may need a boost from lower-intensity, lower-cost anti-obesity medications to reach their goals. Others, with severe obesity or multiple cardio-metabolic conditions, may require higher-intensity anti-obesity medications like GLP-1s. Treatment levels can be safely tried in succession with needs and costs in mind.

It’s likely only 5-10% of a given population would end up using GLP-1s with this step-therapy approach, while the majority of people would still get clinically meaningful results without such intensive treatment.

Address SDOH to personalize care

One-size-fits-all solutions — like those that insist on a highly restrictive diet — miss the mark on health equity. Not everyone can afford expensive meat-heavy diets and they don’t always line up with people’s cultural preferences. Similarly, a program that simply doles out GLP-1s without helping people manage side effects doesn’t work and will only drain budgets.

The key to unlock improved outcomes is by helping people address SDOH challenges like food insecurity, language barriers, cultural factors, physical environment, and more. A good obesity solution should expand access to bilingual registered dietitians who are trained in dietary considerations and eating patterns for many different cultures and ethnic groups. They can help folks plan meals around limited budgets and specific dietary needs.

Conclusion

Organizations have much to consider when evaluating obesity solutions for their population. It’s easy to be swayed by simple metrics that seem indisputable. But, in the end, outcomes like 5% weight loss and reductions in HbA1c for the majority of an eligible population are what counts. Sustainable outcomes rely on real behavior change, a careful step-therapy approach to medication, and personalized care when it comes to social determinants of health.

Caitlyn Edwards, PhD, RDN, is a Senior Clinical Research Specialist at Vida Health

Obesity is crippling the US, but there are solutions

By STEPHANIE TILENIUS

Well over a third of Americans are obese — and the percentage keeps growing at a staggering rate. Over the last twenty years, obesity prevalence grew from 30% to 42% of the US population and rates of severe obesity nearly doubled. If we don’t make serious changes to our healthcare system, it’s scary to think where we’re headed in a few short years.

The fact is, obesity is far from a cosmetic condition. It can be a devastating disease and was classified as such by the American Medical Association in 2013. Obesity is the leading risk factor for deadly diseases like type 2 diabetes, heart disease, stroke, and at least 13 types of cancer.

If we don’t stop the obesity epidemic in its tracks now, we’re in for a world of hurt. People’s lives, the healthcare system, and, by extension, the US economy could be headed for collapse if we continue to ignore it. Cardiometabolic conditions like obesity, heart disease, stroke, and diabetes cost the US healthcare system upwards of $500 billion a year in healthcare costs and another $147 billion in lost workforce productivity for heart disease and stroke alone.

And yet private and government-sponsored health plans are dragging their feet to address obesity head on. They know most people jump from health plan to health plan every few years, so they’re willing to take the chance that their members with obesity won’t develop high-cost complications soon enough to justify treatment now. And yet treatment could reverse the effects of obesity and downstream chronic disease, saving lives and billions of dollars in the long run.

Continue reading…